Breast Cancer Female Clinical Trial
Official title:
Ultrasound Guided (USG) PECS Versus Local Infiltration Anaesthesia (LIA) for Breast Cancer Surgery - A Randomized Quadruple Blinded Efficacy and Safety Study
Breast cancer is the most common cancer for which women in the UK (United Kingdom) undergo surgery. A novel ultrasound guided regional anaesthetic technique called the 'Pecs 2' block has recently been described. This study compares ultrasound guided (USG) Pecs 2 block with local anaesthetic infiltration (LIA) for pain relief following breast cancer surgery.
Breast cancer is the commonest cancer in UK for which women undergo surgery. Pain relief for
breast surgery may be either opioid/morphine based or regional or local anesthetic technique
based. Both have specific advantages and disadvantages. Regional anesthesia is known to
suppress the stress response to surgery by blocking noxious afferent neural input into the
central nervous system. Locoregional anesthetic techniques offer excellent pain relief
without the disadvantages of morphine.These include thoracic epidural anesthesia,
paravertebral block, intercostal blocks and local anesthetic infiltration of the wound. More
recently, a novel ultrasound guided interfascial nerve block technique the 'Pecs block' was
proposed by Blanco et al which provides an alternative method of providing postoperative
analgesia for breast surgery.There is also evidence, albeit limited to support use of local
anesthetic infiltration in breast surgery, which is widely used for analgesia.
Currently, there are no large randomised control trials to prove the safety and efficacy of
ultrasound guided Pecs blocks in breast surgery. Also, wound infiltration with local
anesthetic is practiced widely and to date, there has been no study comparing local
anesthetic wound infiltration with USG pecs blocks.
On this background, we intend to perform a prospective randomised double blinded trial to
evaluate the efficacy and safety of ultrasound guided Pecs blocks for breast surgery by
comparing it local anesthetic wound infiltration.
This is a single-centre, prospective, double blinded randomised case control interventional
study. The study plans to enroll 110 participants.
Patients will be randomly allocated to either group X or Y using computer generated numbers.
Standard monitoring as per AAGBI (Association of anesthetists of Great Britain and Ireland)
guidelines will be instituted as per clinical requirement. All patients will be anaesthetized
using total intravenous anesthesia using TCI (target controlled infusions) of propofol and
remifentanil. Intraoperatively, propofol and remifentanil infusions shall be titrated by the
anesthetist to maintain adequate depth of anesthesia and analgesia.
Following induction of anesthesia and before surgical incision, all patients will receive USG
modified Pecs 2 blocks as described by Blanco et al with 30 mls of pharmacy prepared Drug A
(containing active drug that is 0.25% levobupivacaine) or Drug P (containing placebo 0.9%
NaCl), labelled "PRE" (pre-surgery) respectively based on the group to which they are
allocated.
At the end of surgery, the surgeon shall infiltrate the wound with 30 mls of Drug P or Drug A
respectively, labelled "POST". (post-surgery)
The anesthetist and surgeon doing the interventions will both be blinded as to the
pharmacological contents of the drug. This will be done as previously mentioned with pharmacy
labelling the drugs as "PRE" used for USG pecs block and "POST" for wound infiltration.
Also the observer, in this case the recovery nurse who will be titrating analgesia in the
immediate postoperative period shall be blinded as to what group the patient belongs to.
Intraoperative analgesia will be provided by TCI remifentanil. It shall be supplemented in
all patients with intravenous paracetamol and parecoxib as part of a multimodal analgesic
technique. Following completion of surgery, the patients will be recovered by two dedicated
recovery nurses. The nurses will titrate intravenous morphine in the immediate postoperative
period aiming to keep the NRS (Numerical rating Scale) pain scores below 1.
Observations will be made in the intraoperative & postoperative period looking at relevant
outcome measures. Patients shall be followed up at 1h, 6h and 24 hrs to collect primary
outcome measures. Secondary outcomes will be collected by telephonic follow up at 6 months
and 12 month intervals following surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03080623 -
Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
|
||
Completed |
NCT05527769 -
Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
|
||
Completed |
NCT06376578 -
Exercise Interventions for Improving Health in Breast Cancer Survivors
|
N/A | |
Completed |
NCT03004534 -
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
|
Early Phase 1 | |
Recruiting |
NCT05020574 -
Microbiome and Association With Implant Infections
|
Phase 2 | |
Active, not recruiting |
NCT06277141 -
The Vitality Mammography Messaging Study
|
N/A | |
Completed |
NCT03270111 -
High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women
|
N/A | |
Active, not recruiting |
NCT03917082 -
Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05561842 -
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
|
||
Completed |
NCT04554056 -
Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03127995 -
Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence
|
N/A | |
Active, not recruiting |
NCT02237469 -
Prone Breast Radiotherapy Treatment Planning Observational Study
|
||
Completed |
NCT01204125 -
Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04565054 -
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
|
Phase 3 | |
Not yet recruiting |
NCT06412133 -
Conversations in Light and Shadow: Assessing Phototherapy's Impact on Breast Cancer Patients
|
N/A | |
Recruiting |
NCT03956641 -
Evolution of the Physical Condition in Treated Cancer Patients
|
N/A | |
Recruiting |
NCT06087120 -
Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
|
||
Recruiting |
NCT06058936 -
Exercises Using Virtual Reality on Cancer Patients
|
N/A | |
Completed |
NCT03470935 -
Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger
|
||
Recruiting |
NCT06025604 -
ACTIVPROSEIN : Professional Activity After Breast Cancer
|